Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects

American Journal of Transplantation

Volumn 14, Issue 6, 2014, Pages 1290-1299

  Okimura, K ^a   Maeta, K ^a   Kobayashi, N ^a   Goto, M ^a   Kano, N ^a   Ishihara, T ^a   Ishikawa, T ^a   Tsumura, H ^a   Ueno, A ^a   Miyao, Y ^b   Sakuma, S ^b   Kinugasa, F ^c   Takahashi, N ^a   Miura, T ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

^c ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

CD40; costimulation; immunosuppressive therapy; mAbs

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; HUMAN MONOCLONAL ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY 1240; TETANUS TOXOID; UNCLASSIFIED DRUG; ASKP1240; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BLOOD SAMPLING; CELL PROLIFERATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CROSS REACTION; CYTOTOXICITY; DELAYED HYPERSENSITIVITY; ENDOTHELIUM CELL; GRAFT REJECTION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; JAPANESE WHITE (RABBIT); MACACA FASCICULARIS; MOUSE; NONHUMAN; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RAT; RISK ASSESSMENT; T LYMPHOCYTE; THROMBOEMBOLISM; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; DRUG EFFECTS; FLOW CYTOMETRY; HYPERSENSITIVITY, DELAYED; IMMUNOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD40; CROSS REACTIONS; FLOW CYTOMETRY; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOSUPPRESSIVE AGENTS; MACACA FASCICULARIS; MICE;

EID: 84901376079     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12678     Document Type: Article

References (37)

1. van Kooten C, Banchereau J., CD40-CD40 ligand. J Leukoc Biol 2000; 67: 2-17. (Pubitemid 30046812)
2. Nathan MJ, Yin D, Eichwald EJ, Bishop DK., The immunobiology of inductive anti-CD40L therapy in transplantation: Allograft acceptance is not dependent upon the deletion of graft-reactive T cells. Am J Transplant 2002; 2: 323-332. (Pubitemid 36306898)
3. Remskar M, Li H, Chyu KY, Shah PK, Cercek B., Absence of CD40 signaling is associated with an increase in intimal thickening after arterial injury. Circ Res 2001; 88: 390-394. (Pubitemid 32200111)
4. Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D., Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol 1997; 159: 3104-3108. (Pubitemid 127482065)
5. Gerritse K, Laman JD, Noelle RJ., et al. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 1996; 93: 2499-2504. (Pubitemid 26104798)
6. Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ., Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 1993; 261: 1328-1330. (Pubitemid 24081170)
7. Liu Z, Geboes K, Colpaert S, et al. Prevention of experimental colitis in SCID mice reconstituted with CD45RBhigh CD4+ T cells by blocking the CD40-CD154 interactions. J Immunol 2000; 164: 6005-6014. (Pubitemid 30389849)
8. Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5: 686-693. (Pubitemid 29289433)
9. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997; 94: 8789-8794. (Pubitemid 27335118)
10. Preston EH, Xu H, Dhanireddy KK, et al. IDEC-131 (anti-CD154), sirolimus and donor-specific transfusion facilitate operational tolerance in non-human primates. Am J Transplant 2005; 5: 1032-1041. (Pubitemid 40571251)
11. Schuler W, Bigaud M, Brinkmann V, et al. Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation. Transplantation 2004; 77: 717-726. (Pubitemid 38366978)
12. Kanmaz T, Fechner JJ Jr, Torrealba J, et al. Monotherapy with the novel human anti-CD154 monoclonal antibody ABI793 in rhesus monkey renal transplantation model. Transplantation 2004; 77: 914-920. (Pubitemid 38436834)
13. Knechtle SJ, Hamawy MM, Hu H, Fechner JH Jr, Cho CS., Tolerance and near-tolerance strategies in monkeys and their application to human renal transplantation. Immunol Rev 2001; 183: 205-213. (Pubitemid 34015449)
14. Vincenti F., What's in the pipeline? New immunosuppressive drugs in transplantation. Am J Transplant 2002; 2: 898-903. (Pubitemid 36330218)
15. Larsen CP, Knechtle SJ, Adams A, Pearson T, Kirk AD., A new look at blockade of T-cell costimulation: A therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant 2006; 6: 876-883. (Pubitemid 44356637)
16. Prasad KS, Andre P, Yan Y, Phillips DR., The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease. Curr Opin Hematol 2003; 10: 356-361. (Pubitemid 36936607)
17. Langer F, Ingersoll SB, Amirkhosravi A, et al. The role of CD40 in CD40L- and antibody-mediated platelet activation. Thromb Haemost 2005; 93: 1137-1146. (Pubitemid 40823520)
18. De Reys S, Blom C, Lepoudre B, et al. Human platelet aggregation by murine monoclonal antiplatelet antibodies is subtype-dependent. Blood 1993; 81: 1792-1800. (Pubitemid 23101592)
19. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB., Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000; 6: 114. (Pubitemid 30082329)
20. Andre P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 2002; 8: 247-252. (Pubitemid 34250102)
21. Prasad KS, Andre P, He M, Bao M, Manganello J, Phillips DR., Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc Natl Acad Sci USA 2003; 100: 12367-12371. (Pubitemid 37271566)
22. Haanstra KG, Ringers J, Sick EA, et al. Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates. Transplantation 2003; 75: 637-643. (Pubitemid 36337361)
23. Pearson TC, Trambley J, Odom K, et al. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation 2002; 74: 933-940. (Pubitemid 35191239)
24. Adams AB, Shirasugi N, Jones TR, et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol 2005; 174: 542-550. (Pubitemid 40007445)
25. Laman JD, 't Hart BA, Brok H, et al. Protection of marmoset monkeys against EAE by treatment with a murine antibody blocking CD40 (mu5D12). Eur J Immunol 2002; 32: 2218-2228. (Pubitemid 34965884)
26. Ishida I, Tomizuka K, Yoshida H, et al. Production of human monoclonal and polyclonal antibodies in TransChromo animals. Cloning Stem Cells 2002; 4: 91-102. (Pubitemid 34437643)
27. van der Pol W, van de Winkel JG., IgG receptor polymorphisms: Risk factors for disease. Immunogenetics 1998; 48: 222-232. (Pubitemid 28352188)
28. Imai A, Suzuki T, Sugitani A, et al. A novel fully human anti-CD40 monoclonal antibody, ASKP1240, for kidney transplantation in cynomolgus monkeys. Transplantation 2007; 84: 1020-1028. (Pubitemid 350287383)
29. Aoyagi T, Yamashita K, Suzuki T, et al. A human anti-CD40 monoclonal antibody, ASKP1240, for kidney transplantation in cynomolgus monkeys: Induction and maintenance therapy. Am J Transplant 2009; 9: 1732-1741.
30. Oura T, Yamashita K, Suzuki T, et al. Long-term hepatic allograft acceptance based on CD40 blockade by ASKP1240 in nonhuman primates. Am J Transplant 2012; 12: 1740-1754.
31. Watanabe M, Yamashita K, Suzuki T, et al. ASKP1240, a fully human anti-CD40 monoclonal antibody, prolongs pancreatic islet allograft survival in nonhuman primates. Am J Transplant 2013; 13: 1976-1988.
32. Press OW, Farr AG, Borroz KI, Anderson SK, Martin PJ., Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res 1989; 49: 4906-4912. (Pubitemid 19213646)
33. Inwald DP, McDowall A, Peters MJ, Callard RE, Klein NJ., CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 2003; 92: 1041-1048. (Pubitemid 36588504)
34. Slupsky JR, Kalbas M, Willuweit A, Henn V, Kroczek RA, Müller-Berghaus G., Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thromb Haemost 1998; 80: 1008-1014. (Pubitemid 28556707)
35. Miller DL, Yaron R, Yellin MJ., CD40L-CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression. J Leukoc Biol 1998; 63: 373-379. (Pubitemid 28106852)
36. Xu Y, Szalai AJ, Zhou T, et al. Fc gamma Rs modulate cytotoxicity of anti-Fas antibodies: Implications for agonistic antibody-based therapeutics. J Immunol 2003; 171: 562-568. (Pubitemid 36871362)
37. Crow AR, Leytin V, Starkey AF, Rand ML, Lazarus AH., CD154 (CD40 ligand)-deficient mice exhibit prolonged bleeding time and decreased shear-induced platelet aggregates. J Thromb Haemost 2003; 1: 850-852.